ERBB2 and breast cancer: It was granted first approval in February 2013 for HER2+ metastatic or locally advanced breast cancer based on results of the EMILIA trial (NCT00829166), a large phase III randomized trial comparing progression-free survival (PFS) of lapatinib plus capecitabine vs. ado-trastuzumab emtansine [56].